April 27, 2026
Boston Cell Standards Enters Final Phase of FDA MDDT Program to Qualify First-in-Industry Platform to Standardize Cancer Diagnostic Assays
Continue Reading
December 1, 2025
Calibration Transforms Accuracy in HER2-Low Breast Cancer Testing
International Study Published in Lancet: eBioMedicine BOSTON – November 19, 2025 — Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicine...
Continue Reading
December 20, 2022
National Study Confirms Effectiveness of New Tools for Standardizing Estrogen Receptor Testing
Continue Reading
December 20, 2022
Landmark Study by Boston Cell Standards Validates First Reference Standards for Immunohistochemistry Testing
Continue Reading
December 19, 2022
FDA grants 510(k) clearance for Boston Cell Standards’ IHControls panel
Continue Reading